Summary

The global digital pathology market is expected to grow steadily from USD 1.58 billion in 2026 to USD 2.86 billion by 2031, at a CAGR of 12.5% during the forecast period. The major market driver is the increasing adoption of technologies such as AI, machine learning, cloud-based platforms, and whole-slide imaging systems in pathology practices. Widespread acceptance of digitalization in laboratories and hospitals within the healthcare sector is one of the most significant drivers of market growth. Digital pathology involves scanning, storage, and analysis of tissue slides using digital methods, thereby reducing reliance on microscopy. This improves workflow efficiency and helps pathologists share cases more easily, enabling faster, more accurate diagnosis.

“Brightfield scanners are projected to form the largest segment among whole-slide imaging scanners in the digital pathology market”
Based on whole-slide imaging scanners, brightfield scanners are expected to dominate the market share during the forecast period. Brightfield scanners are expected to be the dominant segment, mainly because brightfield scanning technology is one of the most widely adopted and standardized technologies for routine pathology workflows in hospitals and diagnostic laboratories. Brightfield scanners are usually employed to produce digital images of stained tissue slides, such as hematoxylin and eosin (H&E) stained slides. The digital images produced by brightfield scanners resemble those that pathologists see under a microscope. Due to this reason, the adoption of brightfield scanners has been relatively easy. High accuracy of brightfield scanners has been another important driver for growth in the market.
“By Type, human pathology accounted for the highest share of the digital pathology market”
Based on the type, human pathology accounted for the highest share due to the growing prevalence of chronic and complicated disorders such as cancer. With the growing number of cancer patients, cardiovascular diseases, and other chronic conditions in the global population, there has been a rise in the amount of tissue analysis in hospitals and diagnostic labs. Therefore, there is a high demand for quick and reliable diagnosis methods, which is leading to a rapid adoption of digital pathology in human health care. The use of advanced technologies such as imaging and Artificial Intelligence (AI)-based diagnostic tools is another factor that is fueling the market. Such technologies aid pathologists in analyzing slides faster, recognizing abnormalities, and decision-making in complicated cases.
“APAC to witness the highest growth rate during the forecast period.”
In this report, the digital pathology market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The digital pathology market in APAC is projected to register the highest CAGR during the forecast period. The growth in the APAC market is mainly driven by an increasing focus on digital transformation in hospitals and diagnostic laboratories. Many healthcare systems in the region are transitioning from traditional microscopy to digital pathology platforms, enabling faster image sharing, remote consultation, and improved diagnostic accuracy. This shift is helping hospitals handle rising patient volumes more efficiently. Government initiatives are also playing a major role in market growth. Several countries in the region are promoting digital health adoption through healthcare regulations, funding programs, and national health modernization plans. These initiatives are encouraging hospitals and laboratories to adopt digital pathology systems, especially for cancer diagnosis and large-scale screening programs.

The breakdown of primary participants is as mentioned below:
・By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20%
・By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
・By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%.
Danaher Corporation (US) & F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players in the digital pathology market
・The study includes an in-depth competitive analysis of these key players in the digital pathology market, with their company profiles, recent developments, and key market strategies.

Research Coverage
This research report categorizes the digital pathology market by product (hardware, software, storage systems) by type (human pathology, and veterinary pathology), by technology (conventional digital pathology, AI- enabled digital pathology), by application (clinical diagnostics, pre-clinical research, clinical trials, Telepathology, Academic & Translational Research, Education & Training, Others), by therapeutic area (oncology, hematology, gastrointestinal diseases, infectious diseases, neurology, others), by end-user (hospitals & health systems, diagnostic & reference laboratories, veterinary laboratories, pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutes, others), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital pathology market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, solutions, key strategies, contracts, partnerships, and agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the digital pathology market. This report covers competitive analysis of upcoming startups in the digital pathology market ecosystem.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital pathology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights into the following pointers:
・ Analysis of key drivers (AI-enabled digital pathology improving laboratory throughput, workflow efficiency, and diagnostic accuracy; rising burden of cancer and other chronic diseases increasing pathology testing volumes; expanding adoption of digital pathology in drug discovery, biomarker validation, and clinical research, etc.), restraints (high initial capital investment for scanners, software platforms, and storage infrastructure; data interoperability issues with legacy laboratory and healthcare information systems), opportunities (affordable scanner development enabling adoption in low-resource settings; growth of cloud-native digital pathology platforms and SaaS-based deployment models, etc.), challenges (algorithm validation, explainability, and clinical trust in AI-assisted diagnostics; data privacy, cybersecurity, and patient information protection concerns, etc.)
・ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the digital pathology market
・ Market Development: Comprehensive information about lucrative markets – the report analyses the digital pathology market across varied regions.
・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the digital pathology market
・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Koninklijke Philips N.V. (Netherlands), Sectra AB (Sweden), Hamamatsu Photonics (Japan), Fujifilm Holdings Corporation (Japan), among others, in the digital pathology market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 STUDY SCOPE 41
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 43
1.3.4 CURRENCY CONSIDERED 43
1.4 STAKEHOLDERS 44
1.5 SUMMARY OF CHANGES 44
2 EXECUTIVE SUMMARY 46
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 46
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 48
2.3 DISRUPTIVE TRENDS SHAPING MARKET 49
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 50
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 51
3 PREMIUM INSIGHTS 52
3.1 DIGITAL PATHOLOGY MARKET OVERVIEW 52
3.2 DIGITAL PATHOLOGY MARKET, BY PRODUCT & REGION 53
3.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 56
4.2.1.1 AI-enabled digital pathology improving laboratory throughput, workflow efficiency, and diagnostic accuracy 56
4.2.1.2 Rising burden of cancer and other chronic diseases 57
4.2.1.3 Expanding adoption of digital pathology in drug discovery, biomarker validation, and clinical research 59
4.2.1.4 Growing adoption of computational pathology and advanced image analysis technologies 60
4.2.1.5 Increasing shortage of pathologists driving laboratory digitization and workflow automation 61
4.2.1.6 Rising adoption of telepathology and remote diagnostic workflows 61
4.2.1.7 Growing integration of digital pathology with EHR, PACS, and laboratory information systems 62
4.2.1.8 National cancer screening programs and healthcare digitalization initiatives 62
4.2.2 RESTRAINTS 63
4.2.2.1 High initial capital investment for scanners, software platforms, and storage infrastructure 63
4.2.2.2 Data interoperability issues with legacy laboratory and healthcare information systems 64
4.2.2.3 Regulatory and reimbursement uncertainties across key markets 64
4.2.2.4 Large-scale image storage, archiving, and data management requirements 65
4.2.2.5 Limited standardization across digital pathology workflows, image formats, and deployment practices 66
4.2.3 OPPORTUNITIES 66
4.2.3.1 Growing adoption of digital biomarkers in drug development and clinical research 66
4.2.3.2 Increasing utilization of companion diagnostics and precision oncology applications 67
4.2.3.3 Growth of cloud-native digital pathology platforms and SaaS-based deployment models 68
4.2.3.4 Affordable scanner development enabling adoption in
low-resource settings 69
4.2.4 CHALLENGES 69
4.2.4.1 Shortage of skilled pathologists and technicians 69
4.2.4.2 Algorithm validation, explainability, and clinical trust in Al-assisted diagnostics 70
4.2.4.3 Data privacy, cybersecurity, and patient information protection concerns 70
4.2.4.4 Integration complexity across heterogeneous healthcare IT environments 71
4.3 UNMET NEEDS AND WHITE SPACES 71
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 73
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 THREAT OF NEW ENTRANTS 76
5.1.2 THREAT OF SUBSTITUTES 76
5.1.3 BARGAINING POWER OF SUPPLIERS 76
5.1.4 BARGAINING POWER OF BUYERS 76
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.2 MACROECONOMIC INDICATORS 76
5.2.1 INTRODUCTION 76
5.2.2 GDP TRENDS AND FORECAST 77
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 77
 
5.3 VALUE CHAIN ANALYSIS 78
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 78
5.3.2 COMPONENT AND TECHNOLOGY INFRASTRUCTURE 79
5.3.3 PLATFORM DEVELOPMENT AND INTEGRATION 79
5.3.4 DISTRIBUTION 79
5.3.5 MARKETING AND SALES 79
5.3.6 POST-SALE SERVICES 79
5.4 ECOSYSTEM ANALYSIS 79
5.5 PRICING ANALYSIS 81
5.5.1 INDICATIVE PRICING FOR DIGITAL PATHOLOGY PRODUCTS, BY KEY PLAYERS (2025) 81
5.5.2 INDICATIVE PRICING FOR DIGITAL PATHOLOGY PRODUCTS, BY REGION (2025) 82
5.6 TRADE ANALYSIS 83
5.6.1 IMPORT DATA (HS CODE 901180) 83
5.6.2 EXPORT DATA (HS CODE 901180) 84
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 85
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 86
5.9 INVESTMENT AND FUNDING SCENARIO 87
5.10 CASE STUDY ANALYSIS 88
5.11 IMPACT OF 2025 US TARIFF – DIGITAL PATHOLOGY MARKET 89
5.11.1 INTRODUCTION 89
5.11.2 KEY TARIFF RATES 89
5.11.3 PRICE IMPACT ANALYSIS 90
5.11.4 IMPACT ON COUNTRY/REGION 91
5.11.4.1 US 91
5.11.4.2 Europe 91
5.11.4.3 Asia Pacific 92
5.11.5 IMPACT ON END USERS 92
5.11.5.1 Hospitals and health systems 92
5.11.5.2 Diagnostic and reference laboratories 92
5.11.5.3 Veterinary laboratories 92
5.11.5.4 Pharmaceutical and biotechnology companies 93
5.11.5.5 Contract research organizations 93
5.11.5.6 Academic and research institutes 93
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 94
6.1 KEY EMERGING TECHNOLOGIES 94
6.1.1 CLOUD STORAGE & ARCHIVING 94
6.1.2 WHOLE SLIDE IMAGING (WSI) SCANNERS 94
6.1.3 IMAGE MANAGEMENT SYSTEMS 94
6.1.4 AI-ENABLED IMAGE ANALYSIS & COMPUTATIONAL PATHOLOGY PLATFORMS 95
6.1.5 COMPLEMENTARY TECHNOLOGIES 95
6.1.5.1 LIS, EHR, and PACS integration 95
6.1.5.2 Digital biomarker platform 96
6.1.5.3 Companion diagnostic platforms 96
6.1.5.4 Telepathology & remote collaboration platforms 96
6.1.6 ADJACENT TECHNOLOGIES 97
6.1.6.1 Genomic sequencing 97
6.1.6.2 Multi-omics platforms 97
6.1.6.3 Precision medicine platforms 97
6.2 TECHNOLOGY/PRODUCT ROADMAP 98
6.3 PATENT ANALYSIS 98
6.3.1 PATENT PUBLICATION TRENDS FOR DIGITAL PATHOLOGY MARKET 99
6.3.2 DIGITAL PATHOLOGY PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS 100
6.4 FUTURE APPLICATIONS 103
6.4.1 AI-DRIVEN DIAGNOSTIC DECISION SUPPORT 103
6.4.2 PRECISION MEDICINE & DIGITAL BIOMARKER DEVELOPMENT 103
6.4.3 INTEGRATED PATHOLOGY FOR DRUG DEVELOPMENT & CLINICAL RESEARCH 103
6.5 IMPACT OF GEN AI IN DIGITAL PATHOLOGY MARKET 104
6.5.1 INTRODUCTION 104
6.5.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL PATHOLOGY MARKET 105
6.5.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 106
6.5.3.1 AI-Powered Computational Pathology for Biomarker Discovery at PathAI 106
6.5.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 107
6.5.4.1 AI & computational pathology software market 107
6.5.4.2 Telepathology & remote collaboration market 107
6.5.4.3 Digital biomarker market 108
6.5.5 USER READINESS AND IMPACT ASSESSMENT 108
6.5.5.1 User readiness 108
6.5.5.2 Hospitals & health systems 108
6.5.5.3 Diagnostic & reference laboratories 108
6.5.5.4 Veterinary laboratories 108
6.5.5.5 Pharmaceutical & biotechnology companies 108
6.5.5.6 Contract research organizations (CROs) 109
6.5.5.7 Academic & research institutes 109
6.5.5.8 Impact assessment 109
6.5.5.9 User A: Hospitals and health systems 109
6.5.5.9.1 Implementation 109
6.5.5.9.2 Impact 109
 
6.5.5.10 User B: Diagnostic & reference laboratories 110
6.5.5.10.1 Implementation 110
6.5.5.10.2 Impact 110
6.5.5.11 User C: Veterinary laboratories 110
6.5.5.11.1 Implementation 110
6.5.5.11.2 Impact 110
6.5.5.12 User D: Pharmaceutical & biotechnology companies 110
6.5.5.12.1 Implementation 110
6.5.5.12.2 Impact 111
6.5.5.13 User E: Contract Research Organizations 111
6.5.5.13.1 Implementation 111
6.5.5.13.2 Impact 111
6.5.5.14 User F: Academic & research institutes 111
6.5.5.14.1 Implementation 111
6.5.5.14.2 Impact 111
7 REGULATORY LANDSCAPE 112
7.1 REGIONAL REGULATIONS AND COMPLIANCE 112
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113
7.1.2 REGULATORY FRAMEWORK 118
7.1.2.1 North America 118
7.1.2.2 Europe 119
7.1.2.3 Asia Pacific 119
7.1.2.4 Latin America 120
7.1.2.5 Middle East & Africa 121
7.1.3 INDUSTRY STANDARDS 121
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 123
8.1 INTRODUCTION 123
8.2 DECISION-MAKING PROCESS 123
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 123
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 124
8.3.2 BUYING CRITERIA 125
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 126
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 127
8.5.1 UNMET NEEDS 127
8.5.2 END USER EXPECTATIONS 129
8.6 MARKET PROFITABILITY 130
 
9 DIGITAL PATHOLOGY MARKET, BY PRODUCT 131
9.1 INTRODUCTION 132
9.2 HARDWARE 132
9.2.1 DIGITIZATION OF PATHOLOGY WORKFLOWS AND INCREASING INSTALLATION OF WHOLE-SLIDE IMAGING SYSTEMS TO BOOST MARKET 132
9.2.2 WHOLE SLIDE IMAGING SCANNERS 134
9.2.2.1 Increasing pathology workloads & need for remote consultation driving demand 134
9.2.2.2 Brightfield scanners 137
9.2.2.2.1 Cost-efficient features to boost demand 137
9.2.2.3 Fluorescence scanners 138
9.2.2.3.1 Ability to detect cellular structures and biomarkers to fuel uptake 138
9.2.2.4 Other scanners 139
9.2.3 WORKSTATIONS & VIEWING SYSTEMS 140
9.2.3.1 Rising demand for digital pathology visualization and collaboration tools 140
9.2.4 PERIPHERALS & ACCESSORIES 141
9.2.4.1 Growing laboratory automation and workflow digitization support adoption of pathology accessories 141
9.3 SOFTWARE 142
9.3.1 INCREASING DEMAND FOR REMOTE WORK AND CONSULTATIONS TO BOOST DEMAND 142
9.3.1.1 Enterprise digital pathology solutions/platforms 144
9.3.1.1.1 Growing enterprise-wide digital transformation initiatives drive adoption of integrated pathology platforms 144
9.3.1.2 Image Management Software 145
9.3.1.2.1 Increasing digital slide volumes drive demand for scalable image management solutions 145
9.3.1.3 Image analysis software 146
9.3.1.3.1 Ability to automate quantitative evaluation to support market growth 146
9.3.1.4 AI & computational pathology software 147
9.3.1.4.1 Growing adoption of AI-assisted diagnostics drives rapid market expansion 147
9.4 STORAGE SYSTEMS 148
9.4.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET 148
9.4.1.1 On-premise Storage 150
9.4.1.1.1 Data security, regulatory compliance, and direct infrastructure control support continued adoption 150
9.4.1.2 Cloud Storage 151
9.4.1.2.1 Scalability, remote accessibility, and cost-efficient data management driving growth of cloud-based storage solutions 151
 
9.4.1.3 Hybrid storage 152
9.4.1.3.1 Balance of performance, scalability, and compliance requirements accelerate adoption 152
10 DIGITAL PATHOLOGY MARKET, BY TYPE 154
10.1 INTRODUCTION 155
10.2 HUMAN PATHOLOGY 155
10.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET 155
10.3 VETERINARY PATHOLOGY 156
10.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH 156
11 DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY 158
11.1 INTRODUCTION 159
11.2 CONVENTIONAL DIGITAL PATHOLOGY 159
11.2.1 DIGITIZATION OF PATHOLOGY WORKFLOWS AND ADOPTION OF WHOLE-SLIDE IMAGING TECHNOLOGIES DRIVES MARKET 159
11.3 AI-ENABLED DIGITAL PATHOLOGY 160
11.3.1 ADOPTION OF AI AND COMPUTATIONAL PATHOLOGY TECHNOLOGIES ACCELERATES TRANSITION TO DATA-DRIVEN DIAGNOSTICS 160
12 DIGITAL PATHOLOGY MARKET, BY APPLICATION 162
12.1 INTRODUCTION 163
12.2 CLINICAL DIAGNOSTICS 163
12.2.1 INCREASING CANCER INCIDENCE & GROWING ADOPTION OF AI-FOR ASSISTED DIAGNOSTICS TO DRIVE MARKET 163
12.3 PRE-CLINICAL RESEARCH 165
12.3.1 GROWTH SUPPORTED BY EXPANDING PHARMACEUTICAL AND BIOTECHNOLOGY R&D INVESTMENTS 165
12.3.2 DRUG DISCOVERY & EFFICACY STUDIES 166
12.3.2.1 Growing pharmaceutical R&D investments and rising demand for accelerated therapeutic development 166
12.3.3 TOXICOLOGY AND SAFETY ASSESSMENT 167
12.3.3.1 Increasing regulatory testing requirements and adoption of AI-enabled pathology analysis for standardized safety evaluations to drive market 167
12.3.4 BIOMARKER DISCOVERY & VALIDATION 168
12.3.4.1 Increasing adoption of personalized medicine to boost market 168
12.3.5 OTHER PRE-CLINICAL RESEARCH 169
12.4 CLINICAL TRIALS 170
12.4.1 USE FOR CENTRALIZED REVIEW, PATIENT STRATIFICATION, AND BIOMARKER-BASED CLINICAL STUDIES 170
12.5 TELEPATHOLOGY 171
12.5.1 INCREASING DEMAND FOR REMOTE DIAGNOSTICS AND GROWING SHORTAGE OF PATHOLOGISTS WORLDWIDE TO BOOST GROWTH 171
 
12.6 ACADEMIC & TRANSLATIONAL RESEARCH 172
12.6.1 GROWTH SUPPORTED BY EXPANDING COMPUTATIONAL PATHOLOGY RESEARCH AND INVESTMENTS IN PRECISION MEDICINE 172
12.7 EDUCATION & TRAINING 173
12.7.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH 173
12.8 OTHER APPLICATIONS 174
13 DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA 176
13.1 INTRODUCTION 177
13.2 ONCOLOGY 177
13.2.1 INCREASING ADOPTION OF PRECISION MEDICINE AND DEMAND FOR AI-ASSISTED CANCER DIAGNOSTICS TO BOOST MARKET 177
13.3 HEMATOLOGY 179
13.3.1 IMPLEMENTATION OF AI-POWERED SOLUTIONS FOR BONE MARROW AND BLOOD CELL ANALYSIS TO DRIVE MARKET 179
13.4 GASTROINTESTINAL DISEASE 180
13.4.1 GROWING ADOPTION OF DIGITAL PATHOLOGY SOLUTIONS FOR EARLY DISEASE DETECTION AND DIAGNOSIS TO DRIVE MARKET 180
13.5 INFECTIOUS DISEASE 181
13.5.1 GROWING NEED FOR RAPID AND ACCURATE TISSUE-BASED DIAGNOSTICS TO PROPEL MARKET 181
13.6 NEUROLOGY 182
13.6.1 GROWING NEED FOR RAPID AND ACCURATE TISSUE-BASED DIAGNOSTICS DRIVES GROWTH 182
13.7 OTHERS THERAPEUTIC AREAS 183
14 DIGITAL PATHOLOGY MARKET, BY END USER 185
14.1 INTRODUCTION 186
14.2 HOSPITALS & HEALTH SYSTEMS 186
14.2.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND 186
14.3 DIAGNOSTICS LABORATORIES & REFERENCE LABORATORIES 188
14.3.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 188
14.4 VETERINARY LABORATORIES 189
14.4.1 TECHNOLOGICAL ADVANCEMENTS IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE SUPPORT MARKET GROWTH 189
14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 190
14.5.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET 190
14.6 CONTRACT RESEARCH ORGANIZATION 192
14.6.1 DEMAND FOR OUTSOURCED RESEARCH AND BIOMARKER ANALYSIS SUPPORTS ADOPTION 192
 
14.7 ACADEMIC & RESEARCH INSTITUTES 193
14.7.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 193
14.8 OTHER END USERS 194
15 DIGITAL PATHOLOGY MARKET, BY REGION 196
15.1 INTRODUCTION 197
15.2 NORTH AMERICA 197
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 198
15.2.2 US 204
15.2.2.1 Favorable reimbursements for diagnostics to drive market 204
15.2.3 CANADA 212
15.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market 212
15.3 EUROPE 218
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 218
15.3.2 GERMANY 224
15.3.2.1 High healthcare expenditure and supportive research initiatives to drive market 224
15.3.3 UK 230
15.3.3.1 Government funding investments for pathology services to fuel market 230
15.3.4 FRANCE 237
15.3.4.1 Increasing government funding and favorable insurance system to drive adoption 237
15.3.5 ITALY 242
15.3.5.1 Integration of AI & ML to support market growth 242
15.3.6 SPAIN 247
15.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand 247
15.3.7 SWEDEN 252
15.3.7.1 Increasing prevalence of chronic diseases to support market growth 252
15.3.8 REST OF EUROPE 258
15.4 ASIA PACIFIC 263
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 264
15.4.2 CHINA 269
15.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market 269
15.4.3 JAPAN 275
15.4.3.1 Advanced healthcare infrastructure to support market growth 275
15.4.4 INDIA 280
15.4.4.1 High cancer incidence and rapid healthcare digitization supporting strong growth in digital pathology solutions 280
 
15.4.5 AUSTRALIA 286
15.4.5.1 National digital health initiatives and geographically distributed healthcare networks driving demand 286
15.4.6 SOUTH KOREA 291
15.4.6.1 Regional leadership in digital pathology and AI diagnostics supporting market expansion 291
15.4.7 REST OF ASIA PACIFIC 296
15.5 LATIN AMERICA 301
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 301
15.5.2 BRAZIL 307
15.5.2.1 Biopharma clinical trial demand and Conecte SUS integration catalyzing digital pathology infrastructure 307
15.5.3 MEXICO 312
15.5.3.1 Private sector healthcare expansion and pharmaceutical manufacturing drive digital pathology adoption 312
15.5.4 REST OF LATIN AMERICA 317
15.6 MIDDLE EAST & AFRICA 322
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 322
15.6.2 GCC COUNTRIES 328
15.6.2.1 Saudi Arabia 333
15.6.2.1.1 Vision 2030 health transformation and AI national strategy anchoring pathology digitization investment 333
15.6.2.2 UAE 338
15.6.2.2.1 National AI Strategy 2031 and DHA Digital Health Ecosystem positions country as regional pathology hub 338
15.6.2.3 Other GCC countries 343
15.6.3 SOUTH AFRICA 347
15.6.3.1 Growing demand for diagnostic efficiency and healthcare digitalization initiatives to boost market 347
15.6.4 REST OF MIDDLE EAST & AFRICA 352
16 COMPETITIVE LANDSCAPE 358
16.1 OVERVIEW 358
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 358
16.3 REVENUE ANALYSIS, 2021–2025 361
16.4 MARKET SHARE ANALYSIS, 2025 361
16.5 BRAND COMPARISON 365
16.6 COMPANY VALUATION AND FINANCIAL METRICS 366
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 367
16.7.1 STARS 367
16.7.2 EMERGING LEADERS 367
16.7.3 PERVASIVE PLAYERS 367
16.7.4 PARTICIPANTS 367
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 369
16.7.5.1 Company footprint 369
16.7.5.2 Region footprint 370
16.7.5.3 Product footprint 371
16.7.5.4 Application footprint 372
16.7.5.5 End user footprint 373
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 374
16.8.1 PROGRESSIVE COMPANIES 374
16.8.2 RESPONSIVE COMPANIES 374
16.8.3 DYNAMIC COMPANIES 374
16.8.4 STARTING BLOCKS 374
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 376
16.8.5.1 List of startups/SMES 376
16.9 COMPETITIVE SCENARIO 378
16.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 378
16.9.2 DEALS 379
16.9.3 EXPANSIONS 381
16.9.4 OTHER DEVELOPMENTS 381
17 COMPANY PROFILES 382
17.1 KEY COMPANIES 382
17.1.1 DANAHER CORPORATION 382
17.1.1.1 Business overview 382
17.1.1.2 Products offered 384
17.1.1.3 Recent developments 384
17.1.1.3.1 Product launches & enhancements 384
17.1.1.3.2 Deals 385
17.1.1.3.3 Other developments 386
17.1.1.4 MnM view 386
17.1.1.4.1 Key strengths 386
17.1.1.4.2 Strategic choices 387
17.1.1.4.3 Weaknesses and competitive threats 387
17.1.2 HOFFMANN-LA ROCHE LTD. 388
17.1.2.1 Business overview 388
17.1.2.2 Products offered 389
17.1.2.3 Recent developments 390
17.1.2.3.1 Product launches & approvals 390
17.1.2.3.2 Deals 391
17.1.2.4 MnM view 391
17.1.2.4.1 Key strengths 391
17.1.2.4.2 Strategic choices 392
17.1.2.4.3 Weaknesses and competitive threats 392
 
17.1.3 KONINKLIJKE PHILIPS N.V. 393
17.1.3.1 Business overview 393
17.1.3.2 Products offered 394
17.1.3.3 Recent developments 395
17.1.3.3.1 Product launches & approvals 395
17.1.3.3.2 Deals 396
17.1.3.4 MnM view 397
17.1.3.4.1 Key strengths 397
17.1.3.4.2 Strategic choices 397
17.1.3.4.3 Weaknesses and competitive threats 397
17.1.4 SECTRA AB 398
17.1.4.1 Business overview 398
17.1.4.2 Products offered 399
17.1.4.3 Recent developments 400
17.1.4.3.1 Deals 400
17.1.4.3.2 Other developments 402
17.1.4.4 MnM view 402
17.1.4.4.1 Key strengths 402
17.1.4.4.2 Strategic choices 402
17.1.4.4.3 Weaknesses and competitive threats 402
17.1.5 HAMAMATSU PHOTONICS K.K. 403
17.1.5.1 Business overview 403
17.1.5.2 Products offered 404
17.1.5.3 Recent developments 405
17.1.5.3.1 Deals 405
17.1.5.4 MnM view 405
17.1.5.4.1 Key strengths 405
17.1.5.4.2 Strategic choices 406
17.1.5.4.3 Weaknesses and competitive threats 406
17.1.6 QUANTERIX CORPORATION 407
17.1.6.1 Business overview 407
17.1.6.2 Products offered 408
17.1.6.3 Recent developments 409
17.1.6.3.1 Product launches 409
17.1.6.4 Recent developments 409
17.1.6.4.1 Deals 409
17.1.7 FUJIFILM HOLDINGS CORPORATION 410
17.1.7.1 Business overview 410
17.1.7.2 Products offered 411
17.1.7.3 Recent developments 412
17.1.7.3.1 Deals 412
 
17.1.8 HOLOGIC, INC. 414
17.1.8.1 Business overview 414
17.1.8.2 Products offered 415
17.1.8.3 Recent developments 416
17.1.8.3.1 Product approvals 416
17.1.9 3DHISTECH LTD. 417
17.1.9.1 Business overview 417
17.1.9.2 Products offered 418
17.1.9.3 Recent developments 420
17.1.9.3.1 Product launches & enhancements 420
17.1.9.3.2 Other developments 420
17.1.10 APOLLO ENTERPRISE IMAGING CORP. 421
17.1.10.1 Business overview 421
17.1.10.2 Products offered 421
17.1.10.3 Recent developments 422
17.1.10.3.1 Product enhancements 422
17.1.10.3.2 Deals 422
17.1.11 HURON TECHNOLOGIES INTERNATIONAL INC. 423
17.1.11.1 Business overview 423
17.1.11.2 Products offered 423
17.1.11.2.1 Deals 424
17.1.12 INDICA LABS, LLC. 425
17.1.12.1 Business overview 425
17.1.12.2 Products offered 425
17.1.12.3 Recent developments 426
17.1.12.3.1 Product launches & approvals 426
17.1.12.3.2 Deals 427
17.1.13 OPTRASCAN 429
17.1.13.1 Business overview 429
17.1.13.2 Products offered 429
17.1.13.3 Recent developments 430
17.1.13.3.1 Product launches & approvals 430
17.1.13.3.2 Deals 430
17.1.14 GLENCOE SOFTWARE, INC. 431
17.1.14.1 Business overview 431
17.1.14.2 Products offered 431
17.1.14.3 Recent developments 432
17.1.14.3.1 Product enhancements 432
17.1.15 AIFORIA 433
17.1.15.1 Business overview 433
17.1.15.2 Products offered 433
17.1.15.3 Recent developments 434
17.1.15.3.1 Product launches 434
17.1.15.3.2 Deals 434
17.1.15.3.3 Expansions 436
17.1.16 PAIGE AI, INC. 437
17.1.16.1 Business overview 437
17.1.16.2 Products offered 437
17.1.16.3 Recent developments 438
17.1.16.3.1 Product launches & enhancements 438
17.1.16.3.2 Deals 439
17.1.17 PROSCIA INC. 442
17.1.17.1 Business overview 442
17.1.17.2 Products offered 442
17.1.17.3 Recent developments 443
17.1.17.3.1 Product enhancements & approvals 443
17.1.17.3.2 Deals 444
17.1.17.3.3 Other developments 445
17.1.18 EVIDENT 446
17.1.18.1 Business overview 446
17.1.18.2 Products offered 446
17.1.18.3 Recent developments 447
17.1.18.3.1 Product launches 447
17.1.18.3.2 Deals 447
17.2 OTHER PLAYERS 449
17.2.1 PATHAI, INC. 449
17.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD. 450
17.2.3 MIKROSCAN TECHNOLOGIES, INC. 451
17.2.4 MOTIC DIGITAL PATHOLOGY 452
17.2.5 MORPHLE LABS INC. 453
17.2.6 GRUNDIUM OY 454
17.2.7 CURIOSIS INC. 455
18 RESEARCH METHODOLOGY 456
18.1 RESEARCH APPROACH 456
18.1.1 SECONDARY RESEARCH 457
18.1.1.1 Key data from secondary sources 458
18.1.2 PRIMARY RESEARCH 458
18.1.2.1 Key data from primary sources 460
18.1.2.2 Breakdown of primaries 461
18.1.2.3 Insights from primary experts 461
18.2 RESEARCH METHODOLOGY DESIGN 462
18.3 MARKET SIZE ESTIMATION 463
18.4 MARKET BREAKDOWN DATA TRIANGULATION 468
18.5 MARKET SHARE ESTIMATION 470
18.6 STUDY ASSUMPTIONS 470
18.7 RESEARCH LIMITATIONS 471
18.7.1 METHODOLOGY-RELATED LIMITATIONS 471
18.7.2 SCOPE-RELATED LIMITATIONS 471
18.8 RISK ASSESSMENT 471
19 APPENDIX 472
19.1 DISCUSSION GUIDE 472
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 478
19.3 CUSTOMIZATION OPTIONS 480
19.4 RELATED REPORTS 480
19.5 AUTHOR DETAILS 481